Is it Rational to Continue Anti-Neoplastics with Minimal Toxicity even after Progression in Patients with no other Options? Possibly Yes

DOI QR Code

Sezer, Ahmet (Oncology Clinic, Mustafa Kemal University Medical Faculty) ;
Sumbul, Ahmet Taner (Oncology Clinic, Mustafa Kemal University Medical Faculty) ;
Abali, Huseyin (Oncology Clinic, Mustafa Kemal University Medical Faculty)

Cacheux W, Boisserie T, Staudacher L, et al (2008). Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol, 19, 1651-61.
Grothey A, Sugrue MM, Purdie DM, et al (2008). Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol, 26, 5326-34. https://doi.org/10.1200/JCO.2008.16.3212
Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
Tripathy D, Slamon DJ, Cobleigh M, et al (2004). Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol, 22, 1063-70. https://doi.org/10.1200/JCO.2004.06.557
Zuniga RM, Torcuator R, Jain R, et al (2010). Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol , 99, 237-42 . https://doi.org/10.1007/s11060-010-0121-0